QIAGEN powered by
Analyzing the ancient origins of rare genetic diseases
Over 282,000 mutation entries are now in HGMD Professional
Explore the Spring 2020 Release
Protean BioDiagnostics uses exome sequencing in precision oncology
Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights


integrated databases 


users worldwide


curated findings


new data findings/day


patient tests analyzed

Expert curated genomic and clinical knowledge,
software and services for actionable insights

Accelerated Decisions

Access over 40 genomic, clinical and pharmaceutical databases updated weekly by hundreds of expert curators.

Deeper Insights

Enrich your NGS analysis and interpretations with cutting-edge software solutions trusted by thousands worldwide.

Better Outcomes

Make improvements in life possible by partnering with one provider empowering you from Sample to Insight.

Products from Bench to Bedside

Sample to Insight
DNA Panel Testing

Targeted NGS panels and optimized analysis and interpretation tools. 

Research Bioinformatics Services

Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.

Pharmaceutical Development Services

Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.

Clinical Analysis & Interpretation Services

Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.

Uncover critical and timely insights

QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development. 

Case Study 1

Çukurova University in Adana, Turkey, analyzes the ancient origins of rare genetic diseases

Case Study 2

Scientists at the University of Washington develop new Ebola model and find clues to genetics of host resistance

Case Study 3

Mount Sinai identifies a novel prognostic biomarker associated with treatement response in ovarian cancer patients